DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Anus | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast | Urinary Bladder
What is the purpose of this trial?
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
- Ages18 years and older
- Trial withSouthwest Oncology Group (SWOG)
- Start Date11/19/2017
- End Date08/30/2020
- Last Updated12/04/2018
- Study HIC#2000020739